RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Portfolio Pulse from
Johnson & Johnson's RYBREVANT® and LAZCLUZE™ show significant improvement in overall survival for EGFR-mutated lung cancer patients compared to standard care, with new data presented at ELCC 2025.
March 20, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's new data from the MARIPOSA study shows RYBREVANT® and LAZCLUZE™ significantly improve survival in EGFR-mutated lung cancer, potentially boosting JNJ's oncology portfolio.
The positive results from the MARIPOSA study, showing significant survival benefits over standard care, are likely to enhance JNJ's oncology portfolio and potentially increase its market share in lung cancer treatments. This could lead to a positive short-term impact on JNJ's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100